|
Rhinitis
|
0.210 |
Biomarker
|
disease |
RGD |
Increase in the level of histidine decarboxylase mRNA expression in nasal mucosa of rats sensitized by toluene diisocyanate.
|
15054596 |
2004 |
|
Aggressive behavior
|
0.100 |
Biomarker
|
phenotype |
HPO |
|
|
|
|
Echolalia
|
0.100 |
Biomarker
|
phenotype |
HPO |
|
|
|
|
Sleep disturbances
|
0.100 |
Biomarker
|
phenotype |
HPO |
|
|
|
|
Obsessive compulsive behavior
|
0.100 |
Biomarker
|
disease |
HPO |
|
|
|
|
Dyssomnias
|
0.100 |
Biomarker
|
disease |
HPO |
|
|
|
|
Tic, Motor
|
0.100 |
Biomarker
|
phenotype |
HPO |
|
|
|
|
Tic, Vocal
|
0.100 |
Biomarker
|
phenotype |
HPO |
|
|
|
|
Sleep Disorders
|
0.100 |
Biomarker
|
group |
HPO |
|
|
|
|
Attention deficit hyperactivity disorder
|
0.100 |
Biomarker
|
disease |
HPO |
|
|
|
|
Neoplasms
|
0.060 |
Biomarker
|
group |
BEFREE |
The expression of genes and proteins involved in the biosynthesis (histidine decarboxylase, HDC), action (histamine receptors: HRH1-HRH4), and metabolism of histamine is largely unknown both in the normal human adrenal cortex and in adrenocortical tumors.
|
19568768 |
2009 |
|
Neoplasms
|
0.060 |
Biomarker
|
group |
BEFREE |
We have used both human and Mongolian gerbil tissue, and we evaluated mRNA expression of the neuroendocrine markers chromogranin A and histidine decarboxylase in both normal tissue and poorly differentiated tumor.
|
22688353 |
2013 |
|
Neoplasms
|
0.060 |
Biomarker
|
group |
BEFREE |
Netazepide for 52 weeks: cleared all tumours in 5 patients; cleared all but one tumour in one patient; reduced the number of tumours and size of the largest one in the other patients; normalized CgA in all patients; and reduced mRNA abundances of CgA and histidine decarboxylase in biopsies.
|
27704617 |
2017 |
|
Malignant Neoplasms
|
0.030 |
Biomarker
|
group |
BEFREE |
This method is simple, rapid, sensitive, and quantitative, and allows for the specific identification of cells and tissue expressing HDC, stressing its potential diagnostic usefulness in malignancies in which HDC is described as a new marker.
|
16328055 |
2006 |
|
Malignant Neoplasms
|
0.030 |
Biomarker
|
group |
BEFREE |
Histidine decarboxylase should therefore be considered as a new MC marker in the screen panel of antigens used to diagnose high-grade MC malignancies.
|
16564918 |
2006 |
|
melanoma
|
0.030 |
Biomarker
|
disease |
BEFREE |
HDC has been suggested as a new marker for neuroendocrine differentiation, inflammatory pathologies and several leukemia and highly malignant forms of cancer, such as melanoma and small cell lung carcinoma.
|
16328055 |
2006 |
|
melanoma
|
0.030 |
Biomarker
|
disease |
BEFREE |
Moreover, the decrease in proliferation caused by HDC antisense oligonucleotides indicates considerable functional relevance of histamine synthesis in melanoma growth and suggests a possible in situ application of specific antisense oligonucleotides for HDC in melanoma therapy.
|
11442763 |
2001 |
|
Primary central nervous system lymphoma
|
0.030 |
Biomarker
|
disease |
BEFREE |
This multi-centre, retrospective study reports the outcome of 70 patients undergoing HDC-ASCT for PCNSL in the United Kingdom.
|
28581466 |
2017 |
|
Primary central nervous system lymphoma
|
0.030 |
Biomarker
|
disease |
BEFREE |
The findings suggest that rdWBRT and HDC-ASCT may be associated with delayed neurotoxicity in progression-free patients and underscore the need for long-term follow-up to characterize cognitive dysfunction in PCNSL patients.
|
31377920 |
2019 |
|
Primary central nervous system lymphoma
|
0.030 |
Biomarker
|
disease |
BEFREE |
In this review, we discuss the efficacy, feasibility, and toxicity of HDC/ASCT for PCNSL and its role in the treatment of this aggressive malignancy, both in the first-line and relapse settings.
|
30671909 |
2019 |
|
Carcinogenesis
|
0.030 |
Biomarker
|
phenotype |
BEFREE |
Furthermore, an isogenic HDC-deficient L. reuteri mutant that was unable to generate histamine did not suppress carcinogenesis, indicating a significant role of the cometabolite, histamine, in suppression of chronic intestinal inflammation and colorectal tumorigenesis.
|
28917668 |
2017 |
|
Carcinogenesis
|
0.030 |
Biomarker
|
phenotype |
BEFREE |
Lineage tracing in Hdc-CreERT2;R26-LSL-tdTomato mice revealed that in homeostasis, there is a strong bias by HDC<sup>+</sup> myeloid cells toward the CD11b<sup>+</sup>Ly6G<sup>hi</sup> granulocytic lineage, which was accelerated during azoxymethane/dextran sodium sulfate (AOM/DSS)-induced colonic carcinogenesis.
|
28405523 |
2017 |
|
Carcinoid Tumor
|
0.020 |
Biomarker
|
phenotype |
BEFREE |
HDC should not be considered as a general endocrine marker and HDC IR in bronchial carcinoids and PDNECs of the lung can probably be attributed to a cross-reaction with DDC.
|
16517981 |
2006 |
|
Congestive heart failure
|
0.020 |
Biomarker
|
disease |
BEFREE |
Here, we clarified the roles of HDC-expressing cells and histamine in heart failure post-MI using HDC-EGFP transgenic mice and HDC-knockout (HDC<sup>-/-</sup>) mice.
|
28272448 |
2017 |
|
leukemia
|
0.020 |
Biomarker
|
disease |
BEFREE |
HDC has been suggested as a new marker for neuroendocrine differentiation, inflammatory pathologies and several leukemia and highly malignant forms of cancer, such as melanoma and small cell lung carcinoma.
|
16328055 |
2006 |